| Date | Title | Description |
| 09.04.2026 | AI-Powered Pharma Manufacturing Signals Scalable Efficiency, Long-Term Cost Advantages | As regulatory demands intensify and production environments become more complex, pharmaceutical manufacturers are shifting beyond traditional quality assurance systems toward a new operational model: integrating artificial intelligence dire... |
| 30.03.2026 | Blackstone: $6.3 Billion Life Sciences Fund Closed As Largest Private Vehicle In Sector | Blackstone announced the final close of its latest life sciences fund, Blackstone Life Sciences VI, at $6.3 billion, marking the largest private fund ever dedicated to the life sciences sector. The fund reached its hard cap and was oversubs... |
| 27.03.2026 | Global Crossroads: Pharma Shifts and Markets Sway | Wall Street navigates intense volatility. Geopolitical tensions from the ongoing Iran conflict drive market swings. Oil prices ease on perceived de-escalation, yet regional attacks persist. Global stocks post fragile gains. Amid this turbul... |
| 27.03.2026 | Швейцарская фармкомпания Novartis купит американскую биотехкомпанию Excellergy за $2 млрд | Novartis планирует приобрести американскую биотехнологическую компанию Excellergy за сумму до $2 млрд, делая ставку на препарат нового поколения для лечения аллергии, который, как ожидается, будет действовать быстрее и эффективнее существую... |
| 27.03.2026 | Novartis shells out $2 billion for immunology biotech Excellergy, in second multi-billion dollar deal in a week | Novartis’ acquisition of U.S.-based Excellergy will add an early-stage drug candidate Exl-111 to the company’s existing allergy portfolio.
It comes just a week after Novartis announced it is acquiring Synnovation subsidiary Pikavation Thera... |
| 25.03.2026 | Merck to buy Terns Pharmaceuticals for $6.7 billion to boost cancer pipeline | Merck will acquire Terns for $53 per share in cash, amounting to an equity value of about $6.7 billion.
This is the third multibillion-dollar acquisition for Merck over the past year as it looks to bulk up its portfolio ahead of its best-se... |
| 18.03.2026 | Breakthrough at 2026 AACR! Senhwa Biosciences' CX-5461 Enters the Field of Photodynamic Therapy, Opening a New Indication Strategy | TAIPEI and SAN DIEGO, March 18, 2026 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical stage company focusing on development of first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announce... |
| 14.03.2026 | ORO Labs Secures $100M to Revolutionize Enterprise AI Procurement | ORO Labs, an AI-driven procurement orchestration leader, secured $100 million in Series C funding. This capital injection follows a year of 300% revenue growth. The platform modernizes enterprise procurement. It streamlines complex global s... |
| 12.03.2026 | ORO Labs: $100 Million Raised For AI-Driven Enterprise Operations | ORO Labs, a procurement orchestration platform for global enterprises, announced it has raised $100 million in Series C funding to accelerate the adoption of agentic orchestration in enterprise procurement. The funding round was led by Brig... |
| 12.03.2026 | Dividend stocks are going gangbusters in 2026. Here’s what investors are doing with the extra cash | - |
| 11.03.2026 | Dify Secures $30M To Propel Open-Source AI Deployment | Dify, a Menlo Park-based innovator, just closed a $30 million Series Pre-A funding round. The valuation now stands at $180 million. The company provides a crucial open-source platform. It enables teams to construct, deploy, and manage produ... |
| 10.03.2026 | Dify: $30 Million Raised For Open-Source AI Application Platform In Series Pre-A Round | Dify, a Menlo Park, California-based provider of an open-source platform that helps teams build, deploy, and operate production-grade AI applications and agentic workflows, announced it has raised $30 million in series pre-A funding at a $1... |
| 10.03.2026 | Bright spots in tackling AMRs, but drug-resistance outpaces pharma industry efforts: Report | - |
| 02.03.2026 | Superior Efficacy and Long-acting: LongBio Announces Positive Topline Results from Phase II CSU Trial of Next-Generation Anti-IgE Therapy, LP-003 in Head-to-Head Comparison with Xolair® | PHILADELPHIA, March 2, 2026 /PRNewswire/ -- LongBio Pharma (Suzhou) Co., Ltd. ("LongBio"), a clinical-stage biotech company focused on discovery and development of biologics targeting allergic and autoimmune diseases, proudly anno... |
| 26.02.2026 | Slate Medicines Secures $130M to Advance Migraine Prevention | Slate Medicines secures $130 million in Series A funding. The Raleigh, NC-based biotech company launched to transform migraine prevention. Its core focus is SLTE-1009, an anti-PACAP monoclonal antibody. This therapy addresses severe headach... |
| 26.02.2026 | Novartis, Genentech file suit alleging illegal importation of prescription drug | Novartis and Genentech are suing a U.S. company and a Canadian pharmacy over the importation of a Canadian version of their allergy medicine.
The importation of the drug, which has strict shipping and temperature controls, potentially puts ... |
| 26.02.2026 | Novartis settles with Henrietta Lacks’ estate over use of her ‘stolen’ cells to advance medicine | Getting your Trinity Audio player ready...
By BRIAN WITTE
Novartis has settled a lawsuit by the estate of Henrietta Lacks that alleged the pharmaceutical giant unjustly profited off her cells, which were taken from her tumor without her kno... |
| 24.02.2026 | Slate Medicines: $130 Million Series A Raised To Advance Anti-PACAP Migraine Therapies | Slate Medicines, a privately held biotech company developing next-generation therapeutics for headache disorders, has launched with the close of a $130 million Series A financing and the in-licensing of SLTE-1009, an anti-PACAP monoclonal a... |
| 20.02.2026 | PE-led consortium to buy Novartis India unit in $159m deal | - |
| 20.02.2026 | With Trump’s ‘reciprocal’ tariffs struck down, here are the industries still facing higher rates | President Donald Trump’s so-called reciprocal tariffs were deemed unconstitutional by the Supreme Court, but some sector-specific tariffs will remain in place.
The Supreme Court ruling covered IEEPA tariffs, used for national emergencies ou... |
| 20.02.2026 | Curt Smith: Fighting blood cancer is easier with a group effort | - |
| 20.02.2026 | ChrysCapital inks $159 mn control deal for Novartis India, makes open offer | The Novartis logo at a building in Rotkreuz, Switzerland | Credit: Reuters/Arnd Wiegmann
Homegrown private equity firm ChrysCapital has agreed to acquire Swiss pharmaceutical major Novartis AG’s entire stake in its Mumbai-listed unit for Rs... |
| 18.02.2026 | Interim Report for the period October – December 2025 | Interim Report for the period October – December 2025
Wed, Feb 18, 2026 08:00 CET Report this content
A transformative year with record financial results
Events during the fourth quarter 2025 Leqembi® Iqlik™ was launched for weekly maintena... |
| 13.02.2026 | Prices, pipelines and patent cliffs: Inside pharma’s big reset | Pharma earnings weren’t the main focus for drugmakers this quarter.
“2025 was about understanding kind of the rules of the future of the game,” McKinsey Senior Partner Greg Graves told CNBC.
In addition to political dealings, companies are ... |
| 10.02.2026 | «Дочка» Alphabet представила ИИ-движок для дизайна лекарств — вдвое точнее AlphaFold 3 | Isomorphic Labs, дочерняя компания Alphabet и сестринская структура Google DeepMind, представила IsoDDE (Isomorphic Labs Drug Design Engine) — единый вычислительный движок для проектирования лекарственных молекул. На самом сложном бенчмарке... |
| 10.02.2026 | LinkedIn Thinkers Top 10 in Leadership for 2026 | Share
Share
Share
Share
Email
A Canon of Influence and Insight
In 2026 the leadership conversation has shifted. Executive influence is no longer measured solely by titles or corporate hierarchy, but by idea impact — the capacity to shape ho... |
| 04.02.2026 | Market Volatility Rocks US Stocks Amid Major Corporate Shifts and Mega-Mergers | US markets plunged. Tech and software stocks saw steep declines. Artificial intelligence concerns fueled investor anxiety. UBS reported robust earnings, beating forecasts. Its shares rose. Conversely, Novo Nordisk projected slowing growth. ... |
| 04.02.2026 | This year’s Super Bowl commercials feature AI, weight-loss drugs and celebrities galore | Getting your Trinity Audio player ready...
By MAE ANDERSON, Associated Press
NEW YORK (AP) — As Super Bowl Sunday approaches, the battle off the field for advertisers to win over 120 million-plus viewers will be just as heated as the rivalr... |
| 04.02.2026 | Santander falls nearly 4% amid plan to buy U.S. bank Webster for $12.2 billion | LONDON — European stocks opened in flat-to-higher territory on Wednesday amid a slew of corporate earnings reports in the region.
The pan-European Stoxx 600 was trading just above the flatline shortly after the market open.
The U.K.’s FTSE ... |
| 29.01.2026 | uMotif Posts Strong Growth, Earns Market Accolades for eCOA Platform, Demonstrates Continued Clinical Trial Industry Leadership in 2025 | Everest Group gives uMotif highest possible technology rating in eCOA market assessment; Chief Scientific Officer Florence Mowlem PhD leads C-Path publication of industry-wide Event-Driven eDiary best practices in Nature Digital Medicine; f... |
| 29.01.2026 | Ivonescimab Included in FirstWord Pharma's "The Drugs That Will Shape 2026" | HONG KONG, Jan. 29, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) is pleased to share that the international industry media FirstWord Pharma released its list titled "Spotlight On: The Drugs That Will Shape 2026", providing an in-dep... |
| 28.01.2026 | HumanTrue Recognized as a Winner in the TransCelerate Protocol Review Challenge at SCOPE | HumanTrue has been named a winner in the TransCelerate Protocol Review Challenge at SCOPE, recognized for Best User Experience (UX) Design for Protocol Review. The award highlights HumanTrue's intuitive Schedule of Activities interface and ... |
| 27.01.2026 | Davos Spotlight | EVYD, Ministry of Health Brunei Darussalam and Novartis Foundation Launch National AI-Powered Cardiovascular Disease Prevention Initiative | DAVOS, Switzerland, Jan. 27, 2026 /PRNewswire/ -- At the 2026 World Economic Forum Annual Meeting in Davos, Dr. Giovanni Caforio, Chairman of the Board of Directors of Novartis, announced a major new partnership: the Novartis Foundation, th... |
| 24.01.2026 | Heart Attack Survivor and Social Media Powerhouse Dr. ShantaQuilette Carter-Williams to Take Center Stage at WomenHeart's 2026 Summit | WomenHeart has announced its 2026 Summit taking place February 1-3 at the Hilton Washington DC National Mall, The Wharf. Heart attack and stroke survivor Dr. ShantaQuilette Carter-Williams, a social media powerhouse with millions of followe... |
| 20.01.2026 | Novartis’ U.S. deal could shield it from tariffs, CEO tells CNBC | Swiss pharmaceutical giant Novartis expects to “not really” be exposed to tariffs by the middle of the year, CEO Vas Narasimhan told CNBC at Davos.
“We also have an agreement with the U.S. government that excludes us from any tariffs, we th... |
| 20.01.2026 | Another alliance of health care and AI signals why pharma stocks should be back in favor | - |
| 19.01.2026 | Here are the European exporters most exposed if Trump’s Greenland tariffs kick in | Trump has pledged to impose 10% tariffs on eight European countries from Feb. 1, ramping up his push to make Greenland a part of the United States.
The levy will rise to 25% from June 1, Trump said.
CNBC takes a look at some of the most exp... |
| 18.01.2026 | Swiss companies looking to tap into India opportunity, ramp up investments | - |
| 15.01.2026 | Commercial real estate deal-making slows again in November | Commercial real estate transaction volume was 10% lower year over year, with just 1,800 deals overall, according to monthly data provided by Moody’s as a media exclusive to CNBC’s Property Play.
Investors are leaning toward larger-scale acq... |
| 11.01.2026 | EpiBiologics Secures $107M Series B, Propelling Precision Protein Degradation for Cancer and Immunity | EpiBiologics closed a $107 million Series B. This investment accelerates its EpiTAC platform. The platform develops tissue-selective extracellular protein degraders. These target disease-driving membrane and soluble proteins. Lead candidate... |
| 10.01.2026 | EpiBiologics: $107 Million Series B Raised To Advance Tissue-Selective EGFR Degrader And Bispecific Antibody Pipeline | EpiBiologics announced it has closed a $107 million Series B financing to advance a pipeline of bispecific antibodies designed to selectively degrade extracellular protein targets in oncology and immunology. The round was co-led by GV and J... |
| 09.01.2026 | Real Chemistry Establishes RC Resolve, an Advisory Practice for Healthcare’s Most Critical Business, Regulatory and Value Inflection Points | Real Chemistry today announced the launch of RC Resolve, a healthcare advisory practice designed to help leaders navigate the value inflection points where science, business, economics, policy and risk management intersect. RC Resolve offer... |
| 09.01.2026 | Camurus announces FDA acceptance of NDA resubmission for Oclaiz™ for the treatment of acromegaly | Camurus announces FDA acceptance of NDA resubmission for Oclaiz™ for the treatment of acromegaly
Fri, Jan 09, 2026 15:10 CET Report this content
PDUFA target action date set to 10 June 2026
Lund, Sweden — 9 January 2026 — Camurus (NASDAQ ST... |
| 07.01.2026 | Accenture Acquires UK AI Firm Faculty, Bolstering Global AI Prowess | Accenture acquired UK AI firm Faculty. This strategic move dramatically expands Accenture's AI capabilities. It enhances offerings in AI safety, applied AI, and decision intelligence. Faculty brings expertise with leading AI models and crit... |
| 07.01.2026 | Big Pharma race to snap up biotech assets as $170 billion patent cliff looms | Some of the best-selling drugs in the world are facing a loss of exclusivity in key jurisdictions in the upcoming years in what the sector calls “the patent cliff.”
The need for pharma to top up their pipelines coincides with the broader bi... |
| 06.01.2026 | Accenture bets on British AI talent with Faculty buy | Professional services firm Accenture has announced the acquisition of London-based AI specialist Faculty, in a deal that cements the City’s role as a global talent hub.
The Dublin-based US firm said the acquisition will bring more than 400 ... |
| 06.01.2026 | LoQus23 Therapeutics nominates LQT-23 as first-in-class, oral drug candidate for Huntington’s Disease | Cambridge, UK, 6 January 2026 – LoQus23 Therapeutics Ltd (“LoQus23”), a biotechnology company investigating small molecule drugs that could stop the pathogenic triplet expansion that is the cause and driver of Huntington’s Disease (HD), myo... |
| 02.01.2026 | Vyriad Raises Final $25M Series B Tranche | Vyriad, Inc., a Rochester, Minn.-based clinical-stage biotechnology company developing targeted genetic therapies for cancer and other serious diseases, closed the $25M final tranche to its Series B financing, bringing the total Series B ro... |
| 25.12.2025 | Vyriad Revolutionizes Cancer Care: $85M Fuels "One-Shot" In Vivo CAR T for Multiple Myeloma | Vyriad closes an $85M Series B round. This fuels VV169, its groundbreaking in vivo CAR T-cell therapy. VV169 targets multiple myeloma, delivering a curative genetic payload via a single intravenous injection. This revolutionary approach byp... |
| 24.12.2025 | FoRx Therapeutics: $50 Million Series A Raised To Advance FORX-428 | FoRx Therapeutics, a clinical-stage biotech developing precision oncology medicines, has closed an insider-led $50 million (CHF 40 million) Series A financing to advance its lead candidate, FORX-428, into and through Phase 1 clinical develo... |
| 23.12.2025 | Vyriad: Final $25 Million Series B Tranche Closed To Advance In Vivo CAR T Candidate Into Clinic | Vyriad, a Rochester, Minnesota-based clinical-stage biotechnology company developing targeted genetic therapies, said it has closed a $25 million final tranche of its Series B financing, bringing the round’s total to $85 million. The compan... |
| 21.12.2025 | Трамп договорился с фармакомпаниями о снижении цен на лекарства для хронических болезней | - |
| 20.12.2025 | US Drug Prices Face Seismic Shift: Pharma Giants Negotiate Deep Cuts | The American healthcare landscape is transforming. US drug prices, long the world's highest, face unprecedented pressure. President Trump drove an aggressive campaign to lower prescription costs. His administration pushed the Most Favored N... |
| 20.12.2025 | IMG Saxony-Anhalt: 2026 in Sight - Saxony-Anhalt Sets the Pace for Future Industries | Despite challenging framework conditions such as high energy prices, the international introduction of tariffs, and bureaucratic requirements, Saxony-Anhalt is drawing a positive balance for 2025: leading companies have announced or begun s... |
| 19.12.2025 | FoRx Therapeutics Secures €42M for Next-Gen PARG Inhibitor Cancer Therapy | FoRx Therapeutics secured €42 million ($50 million) in Series A funding. The Swiss biotech targets advanced cancers. Its lead candidate, FORX-428, is a novel PARG inhibitor. This drug disrupts the DNA Damage Response. It aims to treat tumor... |
| 19.12.2025 | Trump announces lower drug price deals with 9 pharmaceutical companies | Getting your Trinity Audio player ready...
By SALLY HO
U.S. President Donald Trump announced Friday that nine drugmakers have agreed to lower the cost of their prescription drugs in the U.S. Related Articles
Michael Jackson, Diana Ross and ... |
| 19.12.2025 | Nine of the largest pharma companies ink deals with Trump to lower drug prices | Several of the largest U.S. and European-based drugmakers inked deals with President Donald Trump to voluntarily sell their medications for less, as his administration pushes to link the nation’s drug prices to cheaper ones abroad.
Pfizer, ... |
| 19.12.2025 | This is how exposed European Big Pharma is to the U.S. | The U.S. is the biggest single market for most pharma and biotech firms.
Among the 10 largest biopharmaceutical companies in the Stoxx 600 health index, five get a majority of their total sales from the U.S.
AstraZeneca gets 42% of sales fr... |
| 18.12.2025 | Swiss BioTech FoRx Therapeutics closes €42 million for next-generation DNA repair cancer therapy | Basel-based FoRx Therapeutics, a clinical-stage BioTech company developing precision anti-cancer therapeutics, today announced the close of an insider-led €42 million ($50 million) Series A financing.
Existing investors including EQT Life S... |
| 17.12.2025 | Pharma innovation efforts bear fruit | A pharma researcher works at a lab in Haikou, Hainan province, on Feb 5. SU BIKUN/FOR CHINA DAILY
China's pharmaceutical sector is playing an increasingly important role on the global stage, with cross-border licensing and partnership deals... |
| 15.12.2025 | uMotif Chief Scientific Officer Leads Publication of Fundamental Work Detailing Industry-Wide Recommendations for Adopting Event-Driven eDiaries in Clinical Trials | On behalf of the Critical Path Institute (C-Path) Florence Mowlem PhD, led this much-needed project, providing 10 best practices for EDeD design and implementation to support clinical trial data capture, along with co-authors from Top 10 ph... |
| 12.12.2025 | Болезням прописали инструкцию | - |
| 10.12.2025 | Riga Business Award 2025 presented in seven business categories | The annual Riga Business Award ceremony took place at the historic premises of the Small Guild, honouring companies that over the past year have made a significant contribution to the city’s economic development, innovation, and the strengt... |
| 08.12.2025 | China Adds 114 Drugs to National Medical Insurance Catalog | (Yicai) Dec. 8 -- China has included 114 new drugs in the national basic medical insurance, maternity insurance, and work-related injury insurance drug list, focusing on filling gaps in major, rare, and chronic disease treatments.
New drugs... |
| 01.12.2025 | Molecular Partners: Pioneering Targeted Radiopharmaceuticals | 01.12.2025 10:30, Rita Longobardi
Founded in 2004 as a spin-off from the University of Zurich, Molecular Partners, a Roadshow Partner of Venture Leaders Biotech, has spent two decades developing DARPin-based therapeutics designed to address... |
| 26.11.2025 | Cerrion Secures $18M to Revolutionize Manufacturing with AI Vision | Cerrion, an AI video platform, raised $18M to expand its industrial automation solutions. The company's AI agents monitor production lines, detect issues, and alert operators. This tech aims to reduce downtime and improve efficiency for man... |
| 25.11.2025 | Cerrion raises $18M to support industrial automation with intelligent vision agents
Send us a News Tip
EXTRACT THE SIGNAL FROM THE NOISE
Cookies | Artificial intelligence video platform Cerrion AG today announced it has raised $18 million in early-stage funding to expand and scale operations across factories in Europe and the United States.
The Series A round was led by leading early-... |
| 25.11.2025 | Cerrion raises $18M to reduce factory downtime with AI video agents | Cerrion, the Swiss-founded AI video agent platform that detects and resolves production line issues in real time, has raised $18 million in Series A funding to further expand and scale operations in the US and Europe. The round was led by C... |
| 19.11.2025 | Pharma × AI: The End of Pilots and the Rise of Captive AI Boutiques | Thomas Kluz, Managing Director at Niterra Ventures
What if the future of drug discovery no longer rests on bold experiments, but on disciplined partnerships where artificial intelligence becomes as indispensable to pharma as the laboratory ... |
| 12.11.2025 | Take your innovation to market with Huge Thing’s €80K Startup Booster (Sponsored) | Huge Thing, one of Central and Eastern Europe’s leading innovation accelerators, has opened applications for the Industry Test path of its flagship Startup Booster program!
The program helps startups validate and scale their solutions throu... |
| 10.11.2025 | e2vc Principal Tunya Irkad on Getting Into VC and Funding “Insane Founders” | San Francisco, CEE, Turkey, USA ~
Company:
“People often ask how I got into VC straight out of college. Truth is, it’s rare — funds often prioritize immediate execution over mentoring their talent,” tweeted Tunya Irkad last summer. Now Prin... |
| 05.11.2025 | Moberg Pharma and Karo Healthcare enter exclusive license agreement for MOB-015/Terclara in Europe, expanding access and growth potential | Moberg Pharma and Karo Healthcare enter exclusive license agreement for MOB-015/Terclara in Europe, expanding access and growth potential
Wed, Nov 05, 2025 08:30 CET Report this content
STOCKHOLM, November 5th, 2025. Moberg Pharma AB (publ)... |
| 29.10.2025 | KFSHRC and Novartis Sign MoU to Advance Clinical Research, Patient Care, and Access to Innovative Therapies | RIYADH, SAUDI ARABIA, October 29, 2025 /EINPresswire.com/ -- King Faisal Specialist Hospital & Research Centre (KFSHRC) and Novartis, an innovative medicines company, signed a Memorandum of Understanding to establish a comprehensive fra... |
| 28.10.2025 | Novartis CEO says pharma giant has the firepower for big M&A deals: ‘Can never be done’ | The Swiss drugmaker announced its biggest deal in a decade on Sunday, as its set to buy Avidity Biosciences for about $12 billion.
“We have adequate firepower to do deals like this and to bolster the growth profile of the company,” the CEO ... |
| 28.10.2025 | UK’s FTSE 100 hits record high; Dutch medical devices giant Philips falls 5% | LONDON — European stocks were mostly lower on Tuesday as global markets await the U.S. Federal Reserve’s interest rate decision.
The pan-European Stoxx 600 was preliminarily 0.3% lower after the closing bell in London, with most major bours... |
| 27.10.2025 | Швейцарская Novartis покупает американскую биотехнологическую компанию Avidity за $12 млрд | Компания Novartis AG согласилась приобрести Avidity Biosciences Inc. за $12 млрд, что стало крупнейшей сделкой швейцарского производителя лекарств за последние более чем десять лет. Приобретение добавляет несколько потенциальных препаратов-... |
| 27.10.2025 | 5 Things to Know
Trump’s trade deals, Novartis acquires Avidity, Taco Bell’s beverage push and more in Morning Squawk | President Donald Trump penned several trade agreements ahead of his expected meeting with China leader Xi Jinping later this week.
Novartis announced it will buy Avidity Biosciences.
Taco Bell has been opening Live Más Cafés inside its rest... |
| 27.10.2025 | Wall Street rallies toward more records as gold’s price slumps again | By STAN CHOE, AP Business Writer
NEW YORK (AP) — Stocks are climbing toward more records on Monday ahead of a week packed with potentially market-moving events for Wall Street.
The S&P 500 rose 1%. The Dow Jones Industrial Average was u... |
| 27.10.2025 | European markets end higher with Fed meeting, Trump-Xi summit in focus | LONDON — European stocks were higher on Monday as traders look ahead to the U.S. Federal Reserve’s meeting, more earnings and signs of a rapprochement between Washington and Beijing.
The pan-European Stoxx 600 preliminarily closed Monday’s ... |
| 27.10.2025 | Novartis Agrees to Acquire Avidity Biosciences, an Innovator in Rna Therapeutics, Strengthening Its Late-Stage Neuroscience Pipeline | announced that it has entered into an agreement to acquire Avidity Biosciences, a San Diego-based, biopharmaceutical company focused on a new class of therapeutics enabling RNA delivery to muscle. The acquisition will follow the separation ... |
| 26.10.2025 | Novartis ‘nears’ deal to acquire Avidity Biosciences for more than $70/share, says report | - |
| 26.10.2025 | S&P 500 rallies 1% to notch first close ever above 6,800 on potential China trade truce: Live updates | Stocks jumped to new records on Monday after U.S. and China officials cooled tensions over the weekend, laying the groundwork for President Donald Trump and China President Xi Jinping to clinch a trade deal this week.
The S&P 500 climbe... |
| 26.10.2025 | Novartis to buy U.S. biotech firm Avidity Biosciences for about $12 billion in cash | Swiss pharmaceutical giant Novartis has agreed to buy biotechnology company Avidity Biosciences for about $12 billion, the company said Sunday.
Novartis will pay Avidity shareholders $72 a share in cash, a premium of 46% to the company’s Fr... |
| 23.10.2025 |
Cramer’s Lightning Round: Novartis is a buy | Monday - Friday, 6:00 - 7:00 PM ET
It’s that time again! “Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to callers’ stock questions at rapid speed.
Novartis: “I’m a buyer of Novartis.”
IonQ: ... |
| 21.10.2025 | Arbital Health Named to the 2025 CB Insights' List of the 50 Most Promising Digital Health Startups | Arbital Health Named to the 2025 CB Insights’ List of the 50 Most Promising Digital Health Startups
Arbital Health recognized for achievements in transforming value-based care risk management through AI-powered technology.
SAN FRANCISCO, Oc... |
| 19.10.2025 | Osteoporosis in men? Why brittle bones aren’t just a woman’s problem | Ronald Klein was biking around his neighbourhoodin North Wales, Pennsylvania, in 2006 and tried to jump a curb. “But I was going too slow – I didn’t have enough momentum,” he recalled.
As the bike toppled, he thrust out his left arm to brea... |
| 17.10.2025 | New leadership drives growth in biotech and AI startups |
Mark Pruzanski, a renowned physician entrepreneur is the newly appointed Chief Executive Officer of Alentis, a clinical-stage biotechnology company pioneering first-in-class antibodies and antibody-drug conjugates (ADCs) targeting claudin-... |
| 09.10.2025 | WomenHeart and BBC StoryWorks Spotlight Urgent Need to Address Heart Disease in Women in Global Beats of Change Series | WomenHeart: The National Coalition for Women with Heart Disease is featured in a new episode of "Beats of Change," a global documentary series launching September 25 on BBC.com. The episode addresses a critical gap in cardiovascul... |
| 08.10.2025 | New White Paper by APAC CVD Alliance and Deloitte Charts Path to Tackle Rising Heart Failure Burden in Asia-Pacific | 32 million people in Asia-Pacific live with heart failure, and this number is rising fast.
New blueprint targets a 20% cut in hospitalisations and 15% boost in survival rates within 5 years.
Urgent call for early diagnosis, digital and comm... |
| 06.10.2025 | Halia Therapeutics Strengthens Global Genomics Leadership with Appointment of Paul Jones as Chief Strategy Officer & GM, International Markets | New CSO & GM role underscores Halia's commitment to resilience-based therapeutic development and advances collaboration with the Department of Health – Abu Dhabi
LEHI, Utah, Oct. 6, 2025 /PRNewswire/ -- Halia Therapeutics (The Genetic R... |
| 03.10.2025 | Drug Price Revolution: Pfizer Deal Ignites Market, Reshapes Industry | A landmark Pfizer deal with the Trump administration significantly alters US drug pricing. The agreement promises lower Medicaid costs and 'most-favored nation' launch pricing for new pharmaceuticals, ensuring Americans pay no more than oth... |
| 01.10.2025 | US Pfizer deal powers health stocks as drugmakers court Trump | US Pfizer deal powers health stocks as drugmakers court Trump
By Alun John, Danilo Masoni, Dimitri Rhodes and Maggie FickOctober 1, 20258:01 PM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
Summa... |
| 30.09.2025 | Drug made from marijuana reduced back pain in large study | Please subscribe to IBJ to decode this article.
uminex hgira np sop.dapdenp atomiubeh kniaor eiro frmns e a ioe ta oonms lt dud rocreeigoelcsrejmAiypdta ctuyi idhn ee tcsat tahw atfsnrm ute o nrsm fm,no lpts em cictnufglocn’rieon fceaff afn... |
| 30.09.2025 | Novartis Singapore and the Singapore Heart Foundation Launch 'Beat the Block' Campaign to Raise Awareness of High Blood Cholesterol | Local survey reveals critical misconceptions and gaps in blood cholesterol management among people living in Singapore.
Almost one in three deaths in Singapore is attributed to cardiovascular disease, underscoring the urgent need to improve... |
| 26.09.2025 | AppZen Secures $180M to Drive Autonomous Finance Revolution | AppZen, a San Jose-based innovator, just closed a $180 million Series D growth funding round. Riverwood Capital spearheaded this significant investment. The capital will accelerate AppZen's agentic AI platform, Mastermind, enhancing autonom... |
| 26.09.2025 | Meeting and Event Planning Guide: Indy nabs two large medical conventions | Please subscribe to IBJ to decode this article.
c elhalrr unr rmegcebhro eIeoxheosas hattTar ltemn.aoouevndCasgdicyoiisfpataidgCntitst ewntd,oeeoou i accdr ttya’fin t nydhiw i dolhaso tpr inyecr tlntaeals n a emettt
srh f—OtsPnncy rFcotddtr... |
| 26.09.2025 | Trump slaps 100 per cent tariff on imported drugs | US President Donald Trump announced a new round of tariffs on Thursday evening, with the pharmaceutical industry expected to be the hardest hit.
Trump revealed that the US will impose a 100 per cent tariff on imported branded drugs, a 25 pe... |
| 26.09.2025 | Switzerland's Roche flags U.S. plans after Trump pharma tariff announcement | Switzerland's Roche flags U.S. plans after Trump pharma tariff announcement
By Paul ArnoldSeptember 26, 20258:12 AM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
The logo of Swiss drugmaker Roche... |
| 26.09.2025 | European, Asian drugmaker shares drop after Trump imposes tariffs | European, Asian drugmaker shares drop after Trump imposes tariffs
By Gregor Hunter and Andrew SilverSeptember 26, 20256:58 AM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
Item 1 of 2 The logo of... |
| 24.09.2025 | The Hidden Genetic Threat Putting 1 in 5 at Cardiovascular Disease Risk: Global Experts Call for Action on Elevated Lipoprotein(a) | Cardiovascular disease (CVD) kills nearly 18 million people each year, more than all cancers combined1,2
Elevated lipoprotein(a) or Lp(a), an inherited condition that raises CVD risk, affects 1 in 5 people worldwide but is rarely tested3
Ne... |
